Biocon
Dipankar Paul has over two decades of experience in the pharmaceutical and biotechnology sectors, currently serving as SBU Head and General Manager for Nephrology & Super Specialty at Biocon since July 2011, after holding various leadership positions including Senior Director and Associate Director in Nephrology. Prior to Biocon, Dipankar Paul worked at Bristol-Myers Squibb as Associate Director in Oncology and held senior marketing roles at Fresenius Kabi and Johnson & Johnson. Earlier career experience includes positions at GlaxoSmithKline, where Dipankar held roles ranging from Product Manager to Senior Pharmaceutical Consultant. Educational qualifications include an Executive Development Program from GSK USA and a degree from Scottish Church College, University of Calcutta, along with foundational education from Calcutta Boys' School.
This person is not in any teams
This person is not in any offices
Biocon
22 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.